Tas-102
Malignant Uterine Corpus Neoplasm
National Cancer Institute (NCI)unclassifiedPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
28 Active assets in the Malignant Uterine Corpus Neoplasm cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Capivasertib M.D. Anderson Cancer Center | Phase 2 | B |
Nivolumab M.D. Anderson Cancer Center | Phase 2 | B |
Palbociclib Pamela Munster | Phase 2 | B |
Tak-228 National Cancer Institute (NCI) | Phase 2 | B |
AZD1775 National Cancer Institute (NCI) | Phase 2 | B |
View all 28 →
Same molecule, other indications
Tas-102 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →